Core Viewpoint - The collaboration between Haixiang Pharmaceutical and Wanbangde Pharmaceutical Group focuses on developing innovative drugs for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, leveraging each company's strengths to enhance their market competitiveness [1] Group 1: Collaboration Details - Haixiang Pharmaceutical signed an "Innovative Drug Cooperation Agreement" with Wanbangde Pharmaceutical on January 12, 2023 [1] - The initial collaboration will focus on the WP205 product, which has received orphan drug designation, and its research and commercialization [1] - Future cooperation will involve small molecule cyclic peptide agonists targeting melanocortin receptors (MCR) in areas such as raw materials and formulations [1] Group 2: Strategic Implications - The partnership aims to effectively integrate resources and complement each other's strengths in the innovative drug sector [1] - Haixiang's involvement in the neurodegenerative disease drug development will expand and deepen its presence in the peptide drug field [1] - This collaboration is expected to enhance Haixiang's existing research pipeline and positively impact its innovative development, thereby improving future market competitiveness [1]

Core Viewpoint - Haisheng Pharmaceutical (002099.SZ) has signed an "Innovative Drug Cooperation Agreement" with Wanbangde Pharmaceutical Holdings Group Co., Ltd., focusing on collaboration for the treatment of amyotrophic lateral sclerosis (ALS) [1] Group 1 - The initial collaboration will concentrate on the development and commercialization of the orphan drug WP205, which has already received orphan drug designation from regulatory authorities [1] - Future cooperation will also include the development of small molecule cyclic peptide agonists targeting melanocortin receptors (MCR) [1]

Core Viewpoint - Haishang Pharmaceutical has signed an innovative drug cooperation agreement with Wanbangde Pharmaceutical to collaborate on the research and commercialization of the WP205 product for amyotrophic lateral sclerosis (ALS) [1] Group 1: Agreement Details - The agreement involves Haishang Pharmaceutical providing 150 million yuan in funding for the development of the WP205 product [1] - Haishang Pharmaceutical will receive 15% of the revenue rights from the commercialization of the product [1] - The agreement is subject to approval by the shareholders' meeting of Wanbangde Pharmaceutical [1] Group 2: Risks - There are risks associated with regulatory policies and market environment that could impact the collaboration [1] - The high-risk nature of drug development is highlighted as a potential concern [1]

Core Viewpoint - Haisheng Pharmaceutical has signed an innovative drug cooperation agreement with Wanbangde Pharmaceutical to collaborate on the development of treatments for amyotrophic lateral sclerosis (ALS) [1] Group 1: Agreement Details - The agreement was signed on January 12, 2026, and focuses initially on the WP205 product, which has already received orphan drug designation [1] - Haisheng Pharmaceutical will invest 150 million yuan, which will be paid in phases according to the agreement [1] - Upon successful collaboration, Haisheng Pharmaceutical will receive 15% of the global commercialization revenue from the WP205 product [1] Group 2: Future Collaboration - The partnership will later expand to include the development of small molecule cyclic peptide agonists, involving both raw materials and formulations [1] - The agreement is subject to approval by the shareholders' meeting of Wanbangde Pharmaceutical Holdings Group Co., Ltd. [1]

证券代码：002099 证券简称：海翔药业 公告编号：2026-002 浙江海翔药业股份有限公司 关于签订创新药合作协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 2、法定代表人：刘同科 特别提示： 1、协议履行过程中，如受到法规政策、市场环境等不可预计或不可抗力因 素的影响，将存在协议无法正常履行的风险。 2、由于药品研发具有高风险、高附加值的特点，药品的前期研发、临床试 验报批到投产的周期长、环节多，容易受到一些不确定性因素的影响。 3、创新药合作协议尚需万邦德医药控股集团股份有限公司股东会审议通过 后生效。 4、公司将根据协议履行情况及后续合作进展，按照证监会、深圳证券交易 所等相关规定及时履行信息披露义务，敬请广大投资者理性投资，注意投资风险。 一、协议签署概况 2026 年 1 月 12 日，浙江海翔药业股份有限公司（以下简称"公司"）与万 邦德医药控股集团股份有限公司全资子公司万邦德制药集团有限公司（以下简称 "万邦德制药"）签订了《创新药合作协议》，双方同意围绕渐冻症适应症，发 挥各自优势，开展相关合作。双方初期合作将聚焦于万邦德制药 ...

Group 1 - The core viewpoint of the news is that Haixiang Pharmaceutical has experienced a significant stock price increase, rising 7.58% on January 9, with a total market value of 11.946 billion yuan and a cumulative increase of 9.94% over four consecutive days [1] - Haixiang Pharmaceutical, established on May 7, 1998, and listed on December 26, 2006, specializes in the production and sales of fine chemicals (intermediates for active pharmaceutical ingredients) and specialty active pharmaceutical ingredients, including antibiotics, antiviral drugs, cardiovascular drugs, antiparasitics, and antidiabetic drugs [1] - The company's main business revenue composition includes 56.07% from active pharmaceutical ingredients and intermediates, 33.09% from dyes and dye intermediates, 9.34% from contract customization, 1.02% from other sources, and 0.49% from formulations [1] Group 2 - Among the top circulating shareholders of Haixiang Pharmaceutical, a fund under Southern Fund holds a significant position, having reduced its holdings by 170,300 shares in the third quarter, now holding 10.3583 million shares, which is 0.64% of the circulating shares [2] - The Southern CSI 1000 ETF (512100), established on September 29, 2016, has a current scale of 76.63 billion yuan, with a year-to-date return of 4.96% and a one-year return of 42.74% [2] - The fund manager of Southern CSI 1000 ETF, Cui Lei, has a tenure of 7 years and 65 days, with a total asset scale of 122.76 billion yuan, achieving a best return of 208.53% and a worst return of -15.93% during the tenure [3]

Group 1 - The core viewpoint of the news is that Haixiang Pharmaceutical experienced a stock price increase of 5.07%, reaching 6.84 CNY per share, with a trading volume of 194 million CNY and a turnover rate of 1.84%, resulting in a total market capitalization of 11.072 billion CNY [1] - Haixiang Pharmaceutical, established on May 7, 1998, and listed on December 26, 2006, is located in Taizhou, Zhejiang Province. The company specializes in the production and sales of fine chemicals (intermediates for active pharmaceutical ingredients) and specialty active pharmaceutical ingredients, including antibiotics, antiviral drugs, cardiovascular drugs, antiparasitics, and hypoglycemic agents [1] - The revenue composition of Haixiang Pharmaceutical includes 56.07% from active pharmaceutical ingredients and intermediates, 33.09% from dyes and dye intermediates, 9.34% from contract customization services, 1.02% from other sources, and 0.49% from formulations [1] Group 2 - Among the top circulating shareholders of Haixiang Pharmaceutical, a fund under Southern Fund holds a significant position. The Southern CSI 1000 ETF (512100) reduced its holdings by 170,300 shares in the third quarter, now holding 10.3583 million shares, which accounts for 0.64% of the circulating shares [2] - The Southern CSI 1000 ETF (512100) was established on September 29, 2016, with a current scale of 76.63 billion CNY. It has achieved a year-to-date return of 3.56%, ranking 2808 out of 5488 in its category, and a one-year return of 42.19%, ranking 1726 out of 4192 [2]

证券代码：002099 证券简称：海翔药业 公告编号：2026-001 浙江海翔药业股份有限公司 关于股份回购进展情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江海翔药业股份有限公司（以下简称"公司"）于 2025 年 4 月 9 日召开 第七届董事会第十三次会议，审议通过了《关于回购股份方案的议案》，同意公 司使用自有/自筹资金以集中竞价交易方式回购部分公司股票（以下简称"本次 回购"），在未来适宜时机用于股权激励或者员工持股计划。本次回购资金总额 不低于人民币 15,000 万元（含），不超过人民币 30,000 万元（含），回购价格 不超过人民币 7.46 元/股（含）。本次回购的实施期限自董事会审议通过本回购 方案之日起 12 个月内。具体内容详见公司于 2025 年 4 月 10 日在《证券时报》 《证券日报》和巨潮资讯网（www.cninfo.com.cn）上披露的《关于回购股份方 案的公告》（公告编号：2025-005）。 根据《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等相关 规定，公司应当在回购期间每个月的前三 ...

Group 1 - The core point of the news is that Haixiang Pharmaceutical experienced a stock price increase of 5.77%, reaching 6.60 CNY per share, with a trading volume of 1.05 billion CNY and a turnover rate of 1.01%, resulting in a total market capitalization of 10.684 billion CNY [1] - Haixiang Pharmaceutical, established on May 7, 1998, and listed on December 26, 2006, is located in Taizhou, Zhejiang Province. The company specializes in the production and sales of fine chemicals (intermediates for active pharmaceutical ingredients) and specialty active pharmaceutical ingredients, including antibiotics, antiviral drugs, cardiovascular drugs, antiparasitics, and hypoglycemic agents [1] - The revenue composition of Haixiang Pharmaceutical includes 56.07% from active pharmaceutical ingredients and intermediates, 33.09% from dyes and dye intermediates, 9.34% from contract customization services, 1.02% from other sources, and 0.49% from formulations [1] Group 2 - From the perspective of Haixiang Pharmaceutical's top ten circulating shareholders, Southern Fund's Southern CSI 1000 ETF (512100) reduced its holdings by 170,300 shares in the third quarter, now holding 10.3583 million shares, which accounts for 0.64% of the circulating shares [2] - The Southern CSI 1000 ETF (512100) was established on September 29, 2016, with a current scale of 76.63 billion CNY. It has achieved a year-to-date return of 29.23%, ranking 1828 out of 4189 in its category [2]

Group 1 - The company, Haishang Pharmaceutical (002099.SZ), confirmed that it currently does not have any assets related to hydrogen energy or lithium resources [1]